The focus of this study was to evaluate the safety and efficacy of sequential peginterferon α-2a (
Pegasys) therapy for chronic hepatitis B with acute exacerbation [ALT > 10 × upper limit of normal (ULN), bilirubin 10 × ULN) plus Pegasys (180 μg/kg/week, when ALT was 5–10 × ULN) for 24 weeks. Thirteen HBeAg-negative patients (Group 2) had the same protocol for 48 weeks. In both groups, entecavir was then discontinued 14 days after the initiation of Pegasys.